PL2780373T3 - Przeciwciała anty il-36r - Google Patents

Przeciwciała anty il-36r

Info

Publication number
PL2780373T3
PL2780373T3 PL12788410T PL12788410T PL2780373T3 PL 2780373 T3 PL2780373 T3 PL 2780373T3 PL 12788410 T PL12788410 T PL 12788410T PL 12788410 T PL12788410 T PL 12788410T PL 2780373 T3 PL2780373 T3 PL 2780373T3
Authority
PL
Poland
Prior art keywords
antibodies
Prior art date
Application number
PL12788410T
Other languages
English (en)
Inventor
Su-Ellen BROWN
Keith Canada
Lukasz CHLEWICKI
Michael Howell
Detlev Mennerich
Joseph Robert WOSKA JR.
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47215803&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2780373(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Publication of PL2780373T3 publication Critical patent/PL2780373T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis
PL12788410T 2011-11-16 2012-11-14 Przeciwciała anty il-36r PL2780373T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161560554P 2011-11-16 2011-11-16
US201261644111P 2012-05-08 2012-05-08
US201261713713P 2012-10-15 2012-10-15
PCT/US2012/064933 WO2013074569A1 (en) 2011-11-16 2012-11-14 Anti il-36r antibodies
EP12788410.4A EP2780373B1 (en) 2011-11-16 2012-11-14 Anti il-36r antibodies

Publications (1)

Publication Number Publication Date
PL2780373T3 true PL2780373T3 (pl) 2020-03-31

Family

ID=47215803

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12788410T PL2780373T3 (pl) 2011-11-16 2012-11-14 Przeciwciała anty il-36r

Country Status (38)

Country Link
US (3) US9023995B2 (pl)
EP (2) EP3536710A1 (pl)
JP (3) JP6289375B2 (pl)
KR (3) KR20200110476A (pl)
CN (3) CN112812183A (pl)
AP (1) AP2014007571A0 (pl)
AR (1) AR089178A1 (pl)
AU (1) AU2012339734B2 (pl)
BR (1) BR112014011594B1 (pl)
CA (1) CA2852994C (pl)
CL (1) CL2014001123A1 (pl)
CO (1) CO7020871A2 (pl)
CY (1) CY1122278T1 (pl)
DK (1) DK2780373T3 (pl)
EA (1) EA031948B1 (pl)
EC (1) ECSP14004976A (pl)
ES (1) ES2755732T3 (pl)
FI (1) FIC20230020I1 (pl)
FR (1) FR23C1023I2 (pl)
HR (1) HRP20191835T1 (pl)
HU (2) HUE047437T2 (pl)
IL (2) IL232100B (pl)
LT (2) LT2780373T (pl)
MX (1) MX347164B (pl)
MY (1) MY195289A (pl)
NL (1) NL301233I2 (pl)
PE (1) PE20142041A1 (pl)
PH (1) PH12014501108A1 (pl)
PL (1) PL2780373T3 (pl)
PT (1) PT2780373T (pl)
RS (1) RS59248B1 (pl)
SG (1) SG11201402283PA (pl)
SI (1) SI2780373T1 (pl)
TW (1) TWI573804B (pl)
UA (1) UA115540C2 (pl)
UY (1) UY34456A (pl)
WO (1) WO2013074569A1 (pl)
ZA (1) ZA201402491B (pl)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012097313A2 (en) 2011-01-14 2012-07-19 The Regents Of The University Of California Therapeutic antibodies against ror-1 protein and methods for use of same
CN112812183A (zh) 2011-11-16 2021-05-18 勃林格殷格翰国际有限公司 抗il-36r抗体
DK2817338T3 (en) 2012-02-24 2017-10-23 Abbvie Stemcentrx Llc DLL3 modulators and methods of use
CN106103484B (zh) * 2014-03-14 2021-08-20 诺华股份有限公司 针对lag-3的抗体分子及其用途
RU2582569C2 (ru) * 2014-07-24 2016-04-27 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Днк, кодирующая полноразмерный антагонист рецептора интерлейкина-36 человека, днк, кодирующая полноразмерный антагонист рецептора интерлейкина-36 человека с с-концевым полигистидиновым тагом, плазмидный экспрессионный вектор (варианты), штамм бактерий escherichia coli bl21 star[de3] (рет-il36raf), - продуцент полноразмерного рецепторного антагониста интерлейкина-36 и штамм бактерий escherichia coli bl21 star[de3] (pet-il36raf-his), - продуцент полноразмерного рецепторного антагониста интерлейкина-36 с с-концевым полигистидиновым тагом
MA41867A (fr) 2015-04-01 2018-02-06 Anaptysbio Inc Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3)
WO2016168542A1 (en) 2015-04-15 2016-10-20 Anaptysbio, Inc. Antibodies directed against interleukin 36 receptor (il-36r)
US10723793B2 (en) * 2015-06-12 2020-07-28 Ludwig Institute For Cancer Research, Ltd. TGF-β3 specific antibodies and methods and uses thereof
JP6654773B2 (ja) * 2015-12-25 2020-02-26 国立大学法人名古屋大学 インターロイキン３６受容体アンタゴニスト欠損症の治療薬
MA50677A (fr) 2016-11-01 2021-07-14 Anaptysbio Inc Anticorps dirigés contre la protéine d'immunoglobuline de lymphocytes t et mucine 3 (tim-3)
MA47206A (fr) 2017-01-09 2019-11-13 Tesaro Inc Méthodes de traitement du cancer au moyen d'anticorps anti-tim-3
CN110461877A (zh) * 2017-03-27 2019-11-15 勃林格殷格翰国际有限公司 抗il-36r抗体联合治疗
AU2019205786B2 (en) * 2018-01-08 2023-12-14 Chemocentryx, Inc. Methods of treating generalized pustular psoriasis with an antagonist of CCR6 or CXCR2
CA3090421A1 (en) * 2018-03-14 2019-09-19 Boehringer Ingelheim International Gmbh Use of anti-il-36r antibodies for treatment of inflammatory bowel disease
KR20200131871A (ko) * 2018-03-14 2020-11-24 베링거 인겔하임 인터내셔날 게엠베하 전신성 농포 건선의 치료를 위한 항-il-36r 항체의 용도
WO2020018503A2 (en) * 2018-07-16 2020-01-23 Regeneron Pharmaceuticals, Inc. Anti-il36r antibodies
CN116200426A (zh) 2018-07-16 2023-06-02 瑞泽恩制药公司 Ditra疾病的非人动物模型及其用途
CN112638946A (zh) 2018-08-16 2021-04-09 坎塔吉亚有限责任公司 抗il1rap抗体组合物
AU2019349958A1 (en) * 2018-09-28 2021-05-06 Kyowa Kirin Co., Ltd. IL-36 antibodies and uses thereof
JP2022514950A (ja) * 2018-12-21 2022-02-16 ２３アンドミー・インコーポレイテッド 抗ｉｌ－３６抗体およびその使用方法
CA3124996A1 (en) 2018-12-27 2020-07-02 Boehringer Ingelheim International Gmbh Il-36r antibodies for treatment of palmoplantar pustulosis
JP7420827B2 (ja) 2019-03-08 2024-01-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｉｌ－３６ｒ抗体製剤
US20220162326A1 (en) * 2019-05-13 2022-05-26 Regeneron Pharmaceuticals, Inc. Anti-il36r antibodies
WO2021112196A1 (ja) * 2019-12-05 2021-06-10 学校法人東京薬科大学 筋組織の減少を抑制するための組成物
AR120913A1 (es) * 2019-12-27 2022-03-30 Teijin Pharma Ltd Anticuerpo que inhibe específicamente la señalización de il-36r
JP2023526359A (ja) 2020-05-19 2023-06-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アトピー性皮膚炎の処置のための抗ｉｌ－３６ｒ抗体
TW202225190A (zh) 2020-07-17 2022-07-01 德商百靈佳殷格翰國際股份有限公司 用於治療嗜中性球性皮膚病之抗-il-36r抗體
EP4188441A1 (en) 2020-07-30 2023-06-07 AnaptysBio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for ichthyosis
WO2022026829A1 (en) 2020-07-30 2022-02-03 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for skin toxicity
MX2023003723A (es) 2020-09-30 2023-04-24 Boehringer Ingelheim Int Anticuerpos anti-il-36r para el tratamiento de dolor inflamatorio cronico.
CN112094349B (zh) * 2020-11-04 2021-02-09 上海华奥泰生物药业股份有限公司 靶向于白介素36r的抗体及其制备方法和应用
WO2022127842A1 (zh) * 2020-12-17 2022-06-23 上海华奥泰生物药业股份有限公司 靶向il-17a和il-36r的双特异性抗体及其应用
WO2022150644A1 (en) 2021-01-08 2022-07-14 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for acne
US20240084021A1 (en) 2021-01-08 2024-03-14 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for hidradenitis suppurativa
WO2022166977A1 (zh) * 2021-02-08 2022-08-11 上海普铭生物科技有限公司 抗人il-36r抗体及其应用
BR112023014103A2 (pt) 2021-03-04 2023-10-10 Boehringer Ingelheim Int Métodos para o tratamento de gpp
US20220290239A1 (en) 2021-03-12 2022-09-15 Boehringer Ingelheim International Gmbh Biomarkers associated with anti-il-36r antibody treatment in generalized pustular psoriasis
KR20240004718A (ko) * 2021-05-03 2024-01-11 베링거 인겔하임 인터내셔날 게엠베하 스페솔리맙의 제조방법
EP4357361A1 (en) * 2021-06-18 2024-04-24 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Anti-il-36r antibody and use thereof
WO2023285362A1 (en) 2021-07-12 2023-01-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of il-36 inhibitors for the treatment of netherton syndrome
WO2023019232A1 (en) 2021-08-13 2023-02-16 Boehringer Ingelheim International Gmbh Anti-il-36r antibodies for the treatment of a fibrotic condition
WO2023052222A2 (en) 2021-09-28 2023-04-06 Boehringer Ingelheim International Gmbh System and method for assessing severity of neutrophilic dermatoses with visible skin manifestation
TW202334200A (zh) 2021-10-28 2023-09-01 美商艾伯維有限公司 抗澱粉樣蛋白β抗體及其使用方法

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
ES2206447T3 (es) 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
MX9305070A (es) 1992-08-21 1994-04-29 Genentech Inc Compocicion farmaceutica que contiene un antagonista de lfa-1 para el tratamiento de transtornos o desordenes mediados por el lfa-1
CA2149329C (en) 1992-11-13 2008-07-15 Darrell R. Anderson Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
DE69836082T2 (de) 1997-08-01 2007-05-10 Schering Corp. Membranproteine aus säugetierzellen; verwandte reagentien
US6416973B1 (en) 1997-08-01 2002-07-09 Schering Corporation Nucleic acids encoding mammalian cell membrane protein MDL-1
ES2528794T3 (es) * 2000-04-11 2015-02-12 Genentech, Inc. Anticuerpos multivalentes y usos de los mismos
EP1627927A3 (en) * 2001-03-01 2006-06-07 Epigenomics AG Methods, systems and computer program products for determining the biological effect and/or activity of drugs, chemical substances and/or pharmaceutical compositions based on their effect on the methylation status of the DNA
CA2499891A1 (en) * 2002-10-03 2004-04-15 Large Scale Biology Corporation Multimeric protein engineering
RU2515108C2 (ru) * 2005-08-19 2014-05-10 Эббви Инк Иммуноглобулин с двойными вариабельными доменами и его применения
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
US8034771B2 (en) 2006-09-08 2011-10-11 Amgen Inc. IL-1F6 polypeptides
EP2152750A1 (en) 2007-04-23 2010-02-17 Schering Corporation Anti-mdl-1 antibodies
CN101802011A (zh) 2007-06-29 2010-08-11 先灵公司 Mdl-1应用
EP2337799A2 (en) * 2008-08-28 2011-06-29 Wyeth LLC Uses of il-22, il-17, and il-1 family cytokines in autoimmune diseases
CN112812183A (zh) 2011-11-16 2021-05-18 勃林格殷格翰国际有限公司 抗il-36r抗体
WO2016168542A1 (en) 2015-04-15 2016-10-20 Anaptysbio, Inc. Antibodies directed against interleukin 36 receptor (il-36r)

Also Published As

Publication number Publication date
HUS2300021I1 (hu) 2023-07-28
AP2014007571A0 (en) 2014-04-30
CN107007833B (zh) 2020-12-11
EA031948B1 (ru) 2019-03-29
JP2015500633A (ja) 2015-01-08
KR102038310B1 (ko) 2019-11-01
PE20142041A1 (es) 2014-12-18
UY34456A (es) 2013-05-31
SI2780373T1 (sl) 2019-12-31
KR20140101738A (ko) 2014-08-20
TW201333037A (zh) 2013-08-16
DK2780373T3 (da) 2019-11-04
KR102159109B1 (ko) 2020-09-23
AU2012339734A1 (en) 2014-04-24
US9023995B2 (en) 2015-05-05
JP2018093885A (ja) 2018-06-21
CA2852994A1 (en) 2013-05-23
NZ623425A (en) 2015-12-24
BR112014011594B1 (pt) 2021-11-09
MX347164B (es) 2017-04-18
AR089178A1 (es) 2014-08-06
IL272035A (en) 2020-02-27
EP2780373B1 (en) 2019-08-21
NL301233I2 (nl) 2023-09-13
WO2013074569A1 (en) 2013-05-23
CN104080808A (zh) 2014-10-01
CN107007833A (zh) 2017-08-04
FR23C1023I1 (fr) 2023-07-21
CY1122278T1 (el) 2020-11-25
SG11201402283PA (en) 2014-06-27
JP6289375B2 (ja) 2018-03-07
PT2780373T (pt) 2019-11-27
KR20190122877A (ko) 2019-10-30
FIC20230020I1 (fi) 2023-06-01
AU2012339734B2 (en) 2017-02-16
ES2755732T3 (es) 2020-04-23
FR23C1023I2 (fr) 2024-03-29
EA201400579A1 (ru) 2014-10-30
US20150203584A1 (en) 2015-07-23
MX2014005759A (es) 2014-09-08
KR20200110476A (ko) 2020-09-23
UA115540C2 (uk) 2017-11-27
PH12014501108B1 (en) 2014-08-04
EP3536710A1 (en) 2019-09-11
MY195289A (en) 2023-01-12
CN104080808B (zh) 2016-11-16
EP2780373A1 (en) 2014-09-24
US20130236471A1 (en) 2013-09-12
BR112014011594A2 (pt) 2017-07-04
NL301233I1 (pl) 2023-06-07
RS59248B1 (sr) 2019-10-31
US20170298135A9 (en) 2017-10-19
LTPA2023518I1 (pl) 2023-06-12
HRP20191835T1 (hr) 2019-12-27
ECSP14004976A (es) 2015-11-30
PH12014501108A1 (en) 2014-08-04
TWI573804B (zh) 2017-03-11
CN112812183A (zh) 2021-05-18
CA2852994C (en) 2023-02-14
LT2780373T (lt) 2019-09-25
IL232100A0 (en) 2014-05-28
HUE047437T2 (hu) 2020-04-28
IL232100B (en) 2020-04-30
JP6719490B2 (ja) 2020-07-08
US10550189B2 (en) 2020-02-04
US20200231684A1 (en) 2020-07-23
JP2020156506A (ja) 2020-10-01
CL2014001123A1 (es) 2015-01-23
ZA201402491B (en) 2021-09-29
CO7020871A2 (es) 2014-08-11

Similar Documents

Publication Publication Date Title
HUS2300021I1 (hu) Anti-IL-36R antitestek
HRP20180640T1 (hr) Anti-b7-h3 antitijelo
IL259826A (en) Anti-alphabetatisiar antibody
GB201103955D0 (en) Antibodies
GB201112056D0 (en) Antibodies
HK1187056A1 (zh) 抗體
LT3219729T (lt) Interleukino-31 monokloninis antikūnas
SG10201609665PA (en) FcɣRIIb-SPECIFIC Fc ANTIBODY
TWI563004B (en) Anti-hxcr1 antibody
EP2714074A4 (en) ANTIBODIES AGAINST EMR1
EP2769988A4 (en) ANTI-GAP43 ANTIBODY
GB201116342D0 (en) Antigen combinations